CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising ...

After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotech’s current shareholders.

The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Currently, there are three CDK4/6 inhibitors approved to treat breast cancer at different stages — Ibrance (chemical name: palbociclib), Kisqali (chemical name: ribociclib), and Verzenio (chemical ...

Abemaciclib (Verzenio / Verzenios / Yulareb / Zenlistik) is a benzimidazole derivative, acts as an anti-tumor or anti-neoplastic agent. It is formulated as tablets and film coated tablets for the oral ...

There are several different CD4/CD6 inhibitors on the market, including Ibrance, Kisqali, and Verzenio. A class of medications called CD4/CD6 inhibitors are being used more and more for women battling ...

One-third of the women were randomly assigned to receive imlunestrant, and another third to receive imlunestrant alongside the targeted therapy drug Verzenio (abemaciclib). The remaining third ...

Verzenio’s label expanded to include the full study population investigated in the Verzenio Phase 3 monarchE trial. Approval supported by four-year data from the monarchE trial; Verzenio added to ...

Verzenio (abemaciclib) has just gained its first approval in HR+/HER2- metastatic breast cancer, but the failure in non-small cell lung cancer (NSCLC) limits the drug's growth options.